What Liver Tests to Order for metALD Assessment
Order AST, ALT, and platelet count as your initial blood tests, then calculate FIB-4 to stratify fibrosis risk 1. These basic tests allow immediate risk stratification and determine whether additional testing is needed.
Initial Blood Work
The foundation of metALD (MASLD) assessment requires three essential laboratory values 1:
- AST (aspartate aminotransferase)
- ALT (alanine aminotransferase)
- Platelet count
These three values enable automatic calculation of FIB-4, the recommended first-line non-invasive fibrosis test. Guidelines strongly recommend that FIB-4 be automatically calculated and systematically reported when liver tests are ordered in at-risk populations 1.
Risk Stratification Using FIB-4
After obtaining basic labs, interpret FIB-4 using age-adjusted thresholds 2:
For patients <65 years old:
- **FIB-4 <1.3**: Low risk—rules out advanced fibrosis with high negative predictive value (>90%)
- FIB-4 1.3-2.67: Indeterminate—proceed to second-tier testing
- FIB-4 >2.67: High risk—proceed to second-tier testing
For patients ≥65 years old:
- FIB-4 <2.0: Low risk threshold (higher cut-off needed due to age effect on score)
- FIB-4 >2.0: Proceed to second-tier testing
Second-Tier Testing for Indeterminate/High FIB-4
When FIB-4 is elevated or indeterminate, you have two evidence-based options 2:
Option 1 (Preferred for FIB-4 near 2.67 or high-risk patients):
- Proceed directly to liver elastography (vibration-controlled transient elastography/VCTE)
- Alternative: Enhanced Liver Fibrosis (ELF) test or other direct fibrosis biomarkers
Option 2 (For FIB-4 1.3-2.67 in lower-risk contexts):
- Implement 1-year lifestyle intervention and cardiometabolic risk factor management
- Retest FIB-4 after 1 year
- If still elevated, proceed to elastography
Additional Considerations
Steatosis Detection
While not required for fibrosis assessment, hepatic steatosis can be detected by 3, 4:
- Ultrasound (first-line imaging for steatosis detection)
- CT or MRI if ultrasound already performed for other indications
- MRI-PDFF (most accurate quantification, but not typically first-line)
Complete Metabolic Panel
Consider adding:
- Albumin (needed for NFS calculation if using that score)
- Glucose/HbA1c (assess diabetes, a component of NFS)
- Lipid panel (assess metabolic dysfunction)
Critical Pitfalls to Avoid
Age-related false positives: FIB-4 overestimates fibrosis risk in older patients. Always use the higher threshold (2.0) for those ≥65 years 2, 1.
Missing 10% of advanced fibrosis: FIB-4 has excellent negative predictive value but will miss approximately 10% of individuals with advanced fibrosis 2. Don't rely on a single normal FIB-4 if clinical suspicion remains high.
Low positive predictive value: FIB-4 in the indeterminate range generates many false positives (PPV <70%) 1. This is why second-tier testing with elastography or ELF is essential before making definitive management decisions.
Unselected population screening: These tests perform poorly in unselected general populations. Only use in patients with metabolic risk factors (obesity, type 2 diabetes, metabolic syndrome) or other liver disease risk factors 1.
Emerging Evidence
Recent research suggests MAF-5 (Metabolic dysfunction-associated fibrosis 5) may outperform FIB-4, particularly in younger patients where age-dependent scores show poor sensitivity 5. However, current guidelines still prioritize FIB-4 due to widespread validation and availability 2, 1.
Liver biopsy is not required for clinical management in most MASLD cases 2. Reserve biopsy for clinical trials, ruling out alternative diagnoses (like autoimmune hepatitis), or when non-invasive tests give conflicting results.